Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

M C T van Zeijl; L C de Wreede; A J M van den Eertwegh; M W J M Wouters; A Jochems; M G Schouwenburg; M J B Aarts; A C J van Akkooi; F W P J van den Berkmortel; J W B de Groot; G A P Hospers; E Kapiteijn; D Piersma; R S van Rijn; K P M Suijkerbuijk; A J Ten Tije; A A M van der Veldt; G Vreugdenhil; J J M van der Hoeven; J B A G Haanen

doi:10.1016/j.ejca.2020.11.028

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

M C T van Zeijl, L C de Wreede, A J M van den Eertwegh, M W J M Wouters, A Jochems, M G Schouwenburg, M J B Aarts, A C J van Akkooi, F W P J van den Berkmortel, J W B de Groot, G A P Hospers, E Kapiteijn, D Piersma, R S van Rijn, K P M Suijkerbuijk, A J Ten Tije, A A M van der Veldt, G Vreugdenhil, J J M van der Hoeven, J B A G Haanen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

258 Downloads (Pure)

Abstract

Background: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice.

Methods: From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from 6 to 48 months were used to assess overall survival (OS) of cases without missing values. The 2017 cohort was excluded from this analysis because of the short follow-up time.

Results: Median OS of the 2013 and 2016 cohort was 11.7 months (95% confidence interval [CI]: 10.4-13.5) and 17.7 months (95% CI: 14.9-19.8), respectively. Compared with the 2013 cohort, the 2016 cohort had superior survival in the Cox model from 0 to 6 months (hazard ratio [HR] = 0.55 [95% CI: 0.43-0.72]) and in the Cox model from 6 to 48 months (HR = 0.68 [95% CI: 0.57-0.83]). Elevated lactate dehydrogenase levels, distant metastases in >= 3 organ sites, brain and liver metastasis and Eastern Cooperative Oncology Group performance score of >= 1 had stronger association with inferior survival from 0 to 6 months than from 6 to 48 months. BRAF-mutated melanoma had superior survival in the first 6 months (HR = 0.50 [95% CI: 0.42-0.59]).

Conclusion(s): Prognosis for advanced melanoma in the Netherlands has improved from 2013 to 2016. Prognostic importance of most evaluated factors was higher in the first 6 months after diagnosis. BRAF-mutated melanoma was only associated with superior survival in the first 6 months. (C) 2020 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	242-251
Number of pages	10
Journal	European Journal of Cancer
Volume	144
Early online date	26-Dec-2020
DOIs	https://doi.org/10.1016/j.ejca.2020.11.028
Publication status	Published - Feb-2021

Keywords

Advanced melanoma
Immunotherapy
Targeted therapy
Real-world
Nationwide
Population-based
PHASE-III TRIALS
POOLED ANALYSIS
METASTATIC MELANOMA
COMBINED NIVOLUMAB
PROGRESSION-FREE
DOUBLE-BLIND
IV MELANOMA
IPILIMUMAB
PEMBROLIZUMAB
VEMURAFENIB

Access to Document

10.1016/j.ejca.2020.11.028

Survival outcomes of patients with advanced melanoma from 2013 to 2017_ Results of a nationwide population-based registryFinal publisher's version, 1.25 MBLicence: Taverne

Handle.net

Persistent link

Cite this

van Zeijl, M. C. T., de Wreede, L. C., van den Eertwegh, A. J. M., Wouters, M. W. J. M., Jochems, A., Schouwenburg, M. G., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., van der Hoeven, J. J. M., & Haanen, J. B. A. G. (2021). Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. European Journal of Cancer, 144, 242-251. https://doi.org/10.1016/j.ejca.2020.11.028

@article{be8c9502c880448abfd885512c020614,

title = "Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry",

abstract = "Background: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice.Methods: From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from 6 to 48 months were used to assess overall survival (OS) of cases without missing values. The 2017 cohort was excluded from this analysis because of the short follow-up time.Results: Median OS of the 2013 and 2016 cohort was 11.7 months (95% confidence interval [CI]: 10.4-13.5) and 17.7 months (95% CI: 14.9-19.8), respectively. Compared with the 2013 cohort, the 2016 cohort had superior survival in the Cox model from 0 to 6 months (hazard ratio [HR] = 0.55 [95% CI: 0.43-0.72]) and in the Cox model from 6 to 48 months (HR = 0.68 [95% CI: 0.57-0.83]). Elevated lactate dehydrogenase levels, distant metastases in >= 3 organ sites, brain and liver metastasis and Eastern Cooperative Oncology Group performance score of >= 1 had stronger association with inferior survival from 0 to 6 months than from 6 to 48 months. BRAF-mutated melanoma had superior survival in the first 6 months (HR = 0.50 [95% CI: 0.42-0.59]).Conclusion(s): Prognosis for advanced melanoma in the Netherlands has improved from 2013 to 2016. Prognostic importance of most evaluated factors was higher in the first 6 months after diagnosis. BRAF-mutated melanoma was only associated with superior survival in the first 6 months. (C) 2020 Elsevier Ltd. All rights reserved.",

keywords = "Advanced melanoma, Immunotherapy, Targeted therapy, Real-world, Nationwide, Population-based, PHASE-III TRIALS, POOLED ANALYSIS, METASTATIC MELANOMA, COMBINED NIVOLUMAB, PROGRESSION-FREE, DOUBLE-BLIND, IV MELANOMA, IPILIMUMAB, PEMBROLIZUMAB, VEMURAFENIB",

author = "{van Zeijl}, {M C T} and {de Wreede}, {L C} and {van den Eertwegh}, {A J M} and Wouters, {M W J M} and A Jochems and Schouwenburg, {M G} and Aarts, {M J B} and {van Akkooi}, {A C J} and {van den Berkmortel}, {F W P J} and {de Groot}, {J W B} and Hospers, {G A P} and E Kapiteijn and D Piersma and {van Rijn}, {R S} and Suijkerbuijk, {K P M} and {Ten Tije}, {A J} and {van der Veldt}, {A A M} and G Vreugdenhil and {van der Hoeven}, {J J M} and Haanen, {J B A G}",

year = "2021",

month = feb,

doi = "10.1016/j.ejca.2020.11.028",

language = "English",

volume = "144",

pages = "242--251",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

van Zeijl, MCT, de Wreede, LC, van den Eertwegh, AJM, Wouters, MWJM, Jochems, A, Schouwenburg, MG, Aarts, MJB, van Akkooi, ACJ, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Ten Tije, AJ, van der Veldt, AAM, Vreugdenhil, G, van der Hoeven, JJM & Haanen, JBAG 2021, 'Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry', European Journal of Cancer, vol. 144, pp. 242-251. https://doi.org/10.1016/j.ejca.2020.11.028

TY - JOUR

T1 - Survival outcomes of patients with advanced melanoma from 2013 to 2017

T2 - Results of a nationwide population-based registry

AU - van Zeijl, M C T

AU - de Wreede, L C

AU - van den Eertwegh, A J M

AU - Wouters, M W J M

AU - Jochems, A

AU - Schouwenburg, M G

AU - Aarts, M J B

AU - van Akkooi, A C J

AU - van den Berkmortel, F W P J

AU - de Groot, J W B

AU - Hospers, G A P

AU - Kapiteijn, E

AU - Piersma, D

AU - van Rijn, R S

AU - Suijkerbuijk, K P M

AU - Ten Tije, A J

AU - van der Veldt, A A M

AU - Vreugdenhil, G

AU - van der Hoeven, J J M

AU - Haanen, J B A G

PY - 2021/2

Y1 - 2021/2

N2 - Background: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice.Methods: From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from 6 to 48 months were used to assess overall survival (OS) of cases without missing values. The 2017 cohort was excluded from this analysis because of the short follow-up time.Results: Median OS of the 2013 and 2016 cohort was 11.7 months (95% confidence interval [CI]: 10.4-13.5) and 17.7 months (95% CI: 14.9-19.8), respectively. Compared with the 2013 cohort, the 2016 cohort had superior survival in the Cox model from 0 to 6 months (hazard ratio [HR] = 0.55 [95% CI: 0.43-0.72]) and in the Cox model from 6 to 48 months (HR = 0.68 [95% CI: 0.57-0.83]). Elevated lactate dehydrogenase levels, distant metastases in >= 3 organ sites, brain and liver metastasis and Eastern Cooperative Oncology Group performance score of >= 1 had stronger association with inferior survival from 0 to 6 months than from 6 to 48 months. BRAF-mutated melanoma had superior survival in the first 6 months (HR = 0.50 [95% CI: 0.42-0.59]).Conclusion(s): Prognosis for advanced melanoma in the Netherlands has improved from 2013 to 2016. Prognostic importance of most evaluated factors was higher in the first 6 months after diagnosis. BRAF-mutated melanoma was only associated with superior survival in the first 6 months. (C) 2020 Elsevier Ltd. All rights reserved.

AB - Background: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice.Methods: From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from 6 to 48 months were used to assess overall survival (OS) of cases without missing values. The 2017 cohort was excluded from this analysis because of the short follow-up time.Results: Median OS of the 2013 and 2016 cohort was 11.7 months (95% confidence interval [CI]: 10.4-13.5) and 17.7 months (95% CI: 14.9-19.8), respectively. Compared with the 2013 cohort, the 2016 cohort had superior survival in the Cox model from 0 to 6 months (hazard ratio [HR] = 0.55 [95% CI: 0.43-0.72]) and in the Cox model from 6 to 48 months (HR = 0.68 [95% CI: 0.57-0.83]). Elevated lactate dehydrogenase levels, distant metastases in >= 3 organ sites, brain and liver metastasis and Eastern Cooperative Oncology Group performance score of >= 1 had stronger association with inferior survival from 0 to 6 months than from 6 to 48 months. BRAF-mutated melanoma had superior survival in the first 6 months (HR = 0.50 [95% CI: 0.42-0.59]).Conclusion(s): Prognosis for advanced melanoma in the Netherlands has improved from 2013 to 2016. Prognostic importance of most evaluated factors was higher in the first 6 months after diagnosis. BRAF-mutated melanoma was only associated with superior survival in the first 6 months. (C) 2020 Elsevier Ltd. All rights reserved.

KW - Advanced melanoma

KW - Immunotherapy

KW - Targeted therapy

KW - Real-world

KW - Nationwide

KW - Population-based

KW - PHASE-III TRIALS

KW - POOLED ANALYSIS

KW - METASTATIC MELANOMA

KW - COMBINED NIVOLUMAB

KW - PROGRESSION-FREE

KW - DOUBLE-BLIND

KW - IV MELANOMA

KW - IPILIMUMAB

KW - PEMBROLIZUMAB

KW - VEMURAFENIB

U2 - 10.1016/j.ejca.2020.11.028

DO - 10.1016/j.ejca.2020.11.028

M3 - Article

C2 - 33373869

SN - 0959-8049

VL - 144

SP - 242

EP - 251

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this